Core Viewpoint - Wolters Kluwer has appointed Greg Samios as the new CEO of its Health division, effective June 1, 2025, succeeding Stacey Caywood [1][4]. Group 1: Leadership and Experience - Greg Samios brings over 25 years of experience in the healthcare sector, having previously served as Executive Vice President of the Health division's largest business units, Clinical Effectiveness and Health Learning, Research, and Practice [2]. - Under Samios's leadership, Wolters Kluwer has seen growth in its clinical decision support and drug information products, including UpToDate and Medi-Span, and he has introduced generative AI into the company's healthcare offerings [2][4]. - Samios has a strong educational background, holding an MBA from Duke University and degrees in Engineering from the University of Rochester [3]. Group 2: Company Overview - Wolters Kluwer is a global leader in information solutions, software, and services across various sectors, including healthcare, tax, accounting, legal, and corporate compliance [6]. - The company reported annual revenues of €5.9 billion in 2024 and operates in over 40 countries, employing approximately 21,900 people [7]. - Wolters Kluwer is listed on Euronext Amsterdam and is included in major indices such as AEX and Euro Stoxx 50 [8].

Core Insights - Wolters Kluwer reported a solid start to 2025 with sustained growth in recurring revenues and margin improvement, reaffirming full-year guidance [4][8][17] Financial Performance - First-quarter revenues increased by 8% in reporting currencies, with organic growth of 5% compared to 6% in 1Q 2024 [5] - Recurring revenues, which constitute 83% of total revenues, grew by 7% organically, consistent with the previous year [5] - Non-recurring revenues declined by 2% organically, with notable growth in Financial & Corporate Compliance and Legal & Regulatory transactional revenues [5][9][10] - Adjusted operating profit increased by 11% at constant currencies, while adjusted free cash flow rose by 5% [8] Segment Performance - Health revenues grew by 3% in constant currencies and 4% organically, with Clinical Solutions achieving 5% organic growth [6] - Tax & Accounting revenues increased by 8% in constant currencies and 5% organically, with cloud software subscriptions growing by 19% [7] - Corporate Performance & ESG revenues saw a 10% increase in constant currencies and organically, driven by strong growth in EHS & ESG solutions [11] Cash Flow and Debt - Cash conversion improved modestly, with adjusted free cash flow increasing by 5% in constant currencies [12] - Net debt stood at €3,347 million as of March 31, 2025, with a net-debt-to-EBITDA ratio of 1.7x [13] Shareholder Returns - The company completed €286 million of its planned €1 billion share buyback program as of May 5, 2025 [8][14] - A proposed total dividend of €2.33 for financial year 2024 represents a 12% increase compared to the previous year [15] Guidance and Outlook - Full-year 2025 guidance remains unchanged, with expectations for organic growth in line with prior year [17][21][22] - Adjusted operating profit margin is anticipated to improve, particularly in Health and Corporate Performance & ESG [17]